The new SenoBright breast imaging technology from GE healthcare, represented in Israel by Eldan, is an excellent tool for early and accurate diagnosis of Breast cancer in Israel.
The first Senobright installation in Israel is now complete at the Breast Imaging Unit in Sheba Medical Center, Ramat Gan.
SenoBright Contrast Enhanced Spectral Mammography (CESM) is an innovative technology which enables physicians to detect and diagnose breast cancer rapidly and accurately, even in the densest part of the breast.
The technology is designed to produce contrast-enhanced mammography images of the breast using iodine-based contrast agent and a dual energy acquisition technique.
SenoBright uses X-rays at multiple energies to create two separate, almost simultaneous, exposures. The images are acquired in familiar mammography views, and can be quickly and easily correlated with standard results.
The resulting images specifically illuminate and highlight areas of contrast uptake, potentially associated with the presence of cancer.
Moreover, it shows potential for measuring the extension of the lesion and helps to plan surgery and treatment.
The CESM exam takes from 5 to 10 minutes and is performed by the same staff, using the same mammography equipment, potentially on the same day as a traditional screening exam, thereby helping medical professionals to cut the critical time patients often have to wait from detection to diagnosis.
GE estimates that by 2020, more than 1 million women worldwide will be examined using SenoBright and this will positively impact the diagnosis results for nearly 250,000 women. SenoBright empowers clinicians to improve care pathways, increase efficiency, and control costs.
Digital mammography is considered a relevant means of breast cancer screening, delivering proven clinical outcomes. The sensitivity and specificity of images can, however, be affected by a range of factors. Dense breast tissue can overlap with lesions, which are not always visible on an X-ray, and radiologists’ interpretation of images can vary.
"If until now inconclusive and ambiguous digital mammography examinations presented a range of challenges, all of which could delay the diagnostic process, the introduction of SenoBright can remove this ambiguity and help ensure that those patients who need cancer treatment will be referred without delay." says Dr. Yael Yagil, Head of Imaging Technologies Department at Eldan.